SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with supp
(vi) Reclassification of comparative information During the year the Group reclassified advances for capital expenditure in the amount of RUB 6 590 061 thousand recognised as other non-current assets as at 31 December 2009 (31 December 2008: RUB 11 868 184 thousand) into property, plant and ...
OJSC MOESK Consolidated Statement of Changes in Equity for the year ended 31 December 2007 '000 RUR Attributable to shareholders of the Company Ordinary share capital Additional paid in Revaluation Retained capital reserve earnings Total Minority interest Total equity At 31 December 2005 Profit for ...
(oral or written) to which Main Street or Piedmont is bound or by which they or their business, capital stock or any of their properties or assets may be affected; (ii) result in the creation or imposition of any material lien, claim, interest, charge, restriction or encumbrance upon any...
Hong Kong financial secretary hails city’s capital market, refutes fund exodus concerns The G7 now leaves the world with only disappointment: Global Times editorial Japan opts for irresponsible sea discharge of its nuclear 湖南华容团洲垸内积水水位累计下降78厘米 The triple significance of the succes...